U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07811726) titled 'The Purpose of This Study is to Evaluate Efficacy and Safety of NT-101 Eye Drops in Patients With Wet Age-Related Macular Degeneration (AMD)' on Aug. 28.
Brief Summary: This phase 2 trial is a randomized, double-blind, placebo-controlled, multicenter study in patients with wet AMD to assess the efficacy and safety of NT-101 topical ophthalmic solution (0.20 mM) administered into the study eye twice daily (BID) for 12 weeks.
Study Start Date: June 11
Study Type: INTERVENTIONAL
Condition:
Wet Age Related Macular Degeneration
Intervention:
DRUG: NT-101 ophthalmic solution
NT-101 is a topical ophthalmic solution containing pigme...